Evidence map›Paper›PMID 41387306›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Multifunctional Nano Immunostimulant: Overcoming Immunosuppressive Microenvironment for Antitumor Immunotherapy.

Guanhong Guo, Wenda Zhong, Huishuang Zhao, Yueying An, Xinyu Dong, Zhengbo Li, Shuangfeng Qin, Guangzhao Xu, Xiangguo Yue, Xudong Wang and 5 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Guanhong GuoSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, P. R. China.
Wenda ZhongSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, P. R. China.ORCID https://orcid.org/0000-0003-0561-9702
Huishuang ZhaoSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, P. R. China.
Yueying AnSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, P. R. China.
Xinyu DongSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, P. R. China.
Zhengbo LiSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, P. R. China.
Shuangfeng QinSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, P. R. China.
Guangzhao XuSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, P. R. China.
Xiangguo YueWeifang University of Science and Technology, Weifang, 262700, P. R. China.
Xudong WangHarway Pharma (Weifang) Co., Ltd, Weifang, 262700, P. R. China.
Wen SunState Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, 116024, P. R. China.
Zhe-Sheng ChenDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, New York, NY, 11439, USA.
Weiguo SongSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, P. R. China.
Liuya WeiSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, P. R. China.
Fahui LiSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, P. R. China.

Funding

Natural Science Foundation of Shandong Province 2024TSGC0514Natural Science Foundation of Shandong Province ZR2023QH218Natural Science Foundation of Shandong Province ZR2025MS1423Shandong Province Medical and Health Science and Technology Project 202302041350Yellow River Delta industry-leading talents DYRC20220203
6 · The paper itself

Abstract

Antitumor immunotherapy has become a pillar therapy by activating the immune system to recognize and attack tumor cells. Yet its efficacy is limited by the immunosuppressive tumor microenvironment (TME) and related mechanisms like hypoxia, high glutathione (GSH) expression, and immune evasion. Due to TME complexity and tumor heterogeneity, monotherapy struggles to modulate immunosuppressive factors for potent results. To solve this, this work develops a multifunctional immune stimulator (3IZH), which can simultaneously boost immunity, downregulate GSH, and alleviate hypoxia. In weakly acidic TME, it releases photosensitizer (3ICy5) and Fe ions. Fe ions consume GSH and relieve hypoxia via redox reactions and hydrogen peroxide decomposition. 3ICy5 accumulates in the endoplasmic reticulum (ER), produces ROS, induces severe ER stress and DAMPs release, triggering immunogenic cell death (ICD). Fe ions and ROS also reduce glutathione peroxidase 4 (GPX4), causing ferroptosis. ICD and ferroptosis activate T cell infiltration to restructure TME. Combined with HIF-1α inhibitor digoxin, 3IZH further reduces HIF-1α resistance, enhances immune cell infiltration, and shows satisfying efficacy in bilateral tumor-bearing mice. The regulatory effect of the immune-suppressive TME, the remarkable therapeutic effect, as well as the safety profile, together indicate the potential of the multifunctional immune stimulator design strategy.

Indexed as

Adjuvants, ImmunologicImmunotherapyNanoparticlesNeoplasmsTumor MicroenvironmentAnimalsCell Line, TumorFerroptosisGlutathioneHumansMicePhotosensitizing AgentsAdjuvants, ImmunologicGlutathionePhotosensitizing Agentsantitumor immunotherapyferroptosisimmunogenic cell deathimmunosuppressive microenvironment

Identifiers

PMID41387306
PMCPMC12948280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.